JY
BDTX icon

Jeff Yass’s Black Diamond Therapeutics BDTX Stock Holding History

Jeff Yass’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.8K Sell
35,011
-43,847
-56% -$107K ﹤0.01% 12734
2026
Q1 		$168K Sell
78,858
-25,866
-25% -$61.5K ﹤0.01% 11877
2025
Q4 		$254K Buy
+104,724
New +$371K ﹤0.01% 10331
2025
Q3 		– Sell
-120,073
Closed -$351K – 12389
2025
Q2 		$298K Buy
120,073
+42,548
+55% +$82K ﹤0.01% 10355
2025
Q1 		$120K Buy
77,525
+42,853
+124% +$89.8K ﹤0.01% 11409
2024
Q4 		$74.2K Buy
+34,672
New +$99.4K ﹤0.01% 11511
2024
Q3 		– Sell
-25,266
Closed -$137K – 11976
2024
Q2 		$118K Sell
25,266
-398,657
-94% -$2.14M ﹤0.01% 10898
2024
Q1 		$2.15M Buy
423,923
+203,613
+92% +$821K ﹤0.01% 5164
2023
Q4 		$619K Buy
220,310
+8,991
+4% +$21.1K ﹤0.01% 8143
2023
Q3 		$606K Buy
211,319
+159,833
+310% +$589K ﹤0.01% 7774
2023
Q2 		$260K Sell
51,486
-56,247
-52% -$115K ﹤0.01% 9730
2023
Q1 		$204K Buy
107,733
+41,919
+64% +$96.3K ﹤0.01% 10553
2022
Q4 		$118K Sell
65,814
-23,782
-27% -$42.8K ﹤0.01% 10778
2022
Q3 		$151K Sell
89,596
-40,805
-31% -$126K ﹤0.01% 11225
2022
Q2 		$321K Buy
130,401
+109,144
+513% +$254K ﹤0.01% 9398
2022
Q1 		$59K Sell
21,257
-17,180
-45% -$62.7K ﹤0.01% 12230
2021
Q4 		$205K Sell
38,437
-23,029
-37% -$161K ﹤0.01% 11386
2021
Q3 		$520K Sell
61,466
-49,083
-44% -$485K ﹤0.01% 9291
2021
Q2 		$1.35M Buy
110,549
+76,219
+222% +$1.51M ﹤0.01% 6937
2021
Q1 		$833K Buy
34,330
+24,826
+261% +$670K ﹤0.01% 8199
2020
Q4 		$305K Buy
+9,504
New +$312K ﹤0.01% 9215

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Jeff Yass's BDTX Position: Q2 2026 in Review

Jeff Yass reduced its Black Diamond Therapeutics (BDTX) stake by 56% in Q2 2026, selling an estimated $107K and leaving 35,011 shares worth $64.8K. The position accounts for ﹤0.01% of the portfolio, ranked #12734.

Jeff Yass first reported a position in BDTX in Q4 2020 and has held it in 21 quarters since. The position peaked at $2.15M in Q1 2024. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Jeff Yass held 35,011 shares of Black Diamond Therapeutics worth $64.8K as of Q2 2026.
  • Jeff Yass sold 43,847 Black Diamond Therapeutics shares in Q2 2026, an estimated $107K.
  • Black Diamond Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12734 holding.
  • Jeff Yass first reported a position in Black Diamond Therapeutics in Q4 2020 and has held it in 21 quarters since.
  • Jeff Yass's Black Diamond Therapeutics position peaked at $2.15M in Q1 2024.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.